Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates.
The binding of methotrexate (MTX) to IgG in conjugates was examined by studies on a direct MTX conjugate with a monoclonal antibody (aMM46) to mouse mammary tumor MM46 cells and corresponding irrelevant antibody and normal gamma-globulin conjugates, all prepared by the active ester method with MTX N-succinimidyl ester (MTX-OSu). The binding was examined in terms of effects on the potency and selectivity of the cytotoxic activity of the aMM46 conjugate. The results obtained supported the following conclusions: (a) MTX-OSu reacts not only with the amino group of IgG to give an amide bond, but also with another group(s) to give a less stable bond(s) such as an ester bond; (b) in contrast to the amide bond-linked MTX, which is taken up by the cells by endocytic internalization, a substantial portion of the MTX linked by an ester or other less stable bond(s) is released from the conjugates extracellularly and enters the cells by the MTX active transport system, as revealed by the inhibitory effect of thiamine pyrophosphate on the cytotoxicity; (c) this MTX linked by a less stable bond(s) that causes nonspecific cytotoxicity can be removed by treatment with hydroxylamine; (d) the overall cytotoxicity of aMM46-MTX decreased on removal of this less stably linked MTX, suggesting that the lysosomal degradation of the conjugate carrying amide bond-linked MTX to liberate MTX derivatives of low molecular weight is insufficient; (e) the liberation of low-molecular-weight substances in the lysosomes is probably more important for efficient entry of active substances into the cytosol, than for inhibition of the activity of dihydrofolate reductase, because after hydroxylamine treatment, the amide bond-linked MTX showed greater decrease in drug cytotoxicity than in inhibitory activity against dihydrofolate reductase; (f) in combination with hydroxylamine treatment, insertion between MTX and IgG of a linkage capable of ready cleavage in lysosomes deserves exploitation as a method for making potent conjugates with less nonspecific activity.
Endo
N
N
Department of Medicinal Chemistry and Biochemistry, Teijin Institute for Biomedical Research, Tokyo, Japan.
Takeda
Y
Y
Umemoto
N
N
Kishida
K
K
Watanabe
K
K
Saito
M
M
Kato
Y
Y
Hara
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D002470:Cell Survival / Q000187:drug effects; D004355:Drug Stability; D005493:Folic Acid Antagonists; D019811:Hydroxylamine; D006898:Hydroxylamines / Q000494:pharmacology; D007074:Immunoglobulin G / Q000008:administration & dosage*; D000922:Immunotoxins / Q000378:metabolism* / Q000494:pharmacology; D008727:Methotrexate / Q000008:administration & dosage* / Q000494:pharmacology; D051379:Mice; D008809:Mice, Inbred C3H; D012709:Serum Albumin / Q000008:administration & dosage; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D005493:Folic Acid Antagonists; D006898:Hydroxylamines; D007074:Immunoglobulin G; D000922:Immunotoxins; D012709:Serum Albumin; D019811:Hydroxylamine; D008727:Methotrexate